Clinical trials: Inflammatory Bowel Disease (IBD)
Colorectal Cancer, Precancerous Lesion
Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of CRC
Colorectal cancer (CRC) has become one of the most common malignant tumors in the world, and the key to its prevention and control is early detection and treatment.
- Conditions
- Colorectal Cancer, Precancerous Lesion, Inflammatory Bowel Diseases
- Trial name
- NCT05530746
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
- Trial name
- PSC (NCT01802073)
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Stanford University
Ulcerative Colitis
Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis
Confirmation of safety profile
- Trial name
- NCT01517594
- Where
- 30 sites in Czechia
- Volunteers
- 568 people
- Sponsor
- Ferring Pharmaceuticals
Crohn's Disease
Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.
- Trial name
- NCT00275418
- Testing
- beta carotene from Dunaliella algae
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Bnai Zion Medical Center
Crohn's Disease
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation.
- Trial name
- NCT00048113
- Testing
- Alicaforsen
- Where
- 30 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Crohn Disease
An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery.
- Trial name
- NCT01090817
- Testing
- Mesenchymal stromal cells (MSC) for infusion
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- R.P.Herrmann
Crohn's Disease
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein [hs-CRP] and…
- Trial name
- CALM (NCT01235689)
- Testing
- Adalimumab, Prednisone, Azathioprine
- Volunteers
- 252 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis (UC)
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
It's of great importance to effectively induce and maintain disease remission in patients with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT06095596
- Testing
- Upadacitinib, Vedolizumab
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
- Trial name
- CD04 (NCT00739986)
- Testing
- Semapimod
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 152 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease (CD)
Health Benefits of Tart Cherry in Crohn's Disease
Crohn's disease (CD) is a long-term inflammatory condition of the digestive tract. People with CD often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue.
- Trial name
- NCT06901986
- Testing
- Montmorency tart cherry
- Volunteers
- 52 people
- Sponsor
- University of Central Lancashire
Rectovaginal Fistula, Crohn Disease
Treatment of Rectovaginal Crohn's Fistula by Combination of TAAM Injection and Biological Plug Placement
Interventional, prospective, randomized, controlled, double blind, parallel groups, nonprofit, single center trial
- Trial name
- LIPOPLUG (NCT06813768)
- Testing
- Microfractured adipose tissue injection and plug placement
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Intestinal Disease, Inflammatory Bowel Diseases
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate…
- Conditions
- Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer
- Trial name
- NCT04573959
- Testing
- SV-3 Capsule Endoscopy
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Capso Vision, Inc.
Pronase, Mucosal Clarity
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Pronase is a proteolytic enzyme known for its ability to clear mucus by breaking down its main component, mucin, through enzymatic hydrolysis.
- Trial name
- NCT06874673
- Testing
- Pronase
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Changhai Hospital
Crohn Disease
Biologics and Partial Enteral Nutrition Study
Crohn's disease (CD) is a chronic, incurable condition associated with inflammation in the gut lining. It causes diarrhoea, severe abdominal pain, poor nutrition and adversely affects the quality of life of sufferers.
- Trial name
- BIOPIC (NCT04859088)
- Testing
- Partial Enteral Nutrition
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Crohn's Disease, Ulcerative Colitis
The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases (IBD) are life-long, incurable illnesses that can have a profound effect on the patients quality of life.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Anxiety
- Trial name
- NCT01916161
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 307 people
- Sponsor
- National Health Service, United Kingdom
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
- Trial name
- SHIFT-IBD (NCT07245394)
- Testing
- Guselkumab (Tremfya)
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- TIDHI Innovation Inc.
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD)
Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD), Ulcerative Colitis (UC), Artificial Intelligence (AI)
- Trial name
- NCT07590271
- Where
- Taiwan
- Volunteers
- 4,500 people
- Sponsor
- Taichung Veterans General Hospital
Prospective Study, Ulcerative Colitis in Remission
A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis
Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for…
- Trial name
- NCT03698812
- Testing
- Colonoscope
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Colitis, Ulcerative
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.
- Trial name
- NCT03531892
- Testing
- AJM300
- Where
- 82 sites in Japan
- Volunteers
- 198 people
- Sponsor
- EA Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.